TrialEuropean journal of cancer (Oxford, England : 1990)2019

Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.

M Martín et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.